Itraconazole Capsule 100 mg (Itraconazole)

Adult dosage

To increase absorption, this medicine should preferably be administered immediately after a meal. The capsules must be swallowed whole. 1. Short-term treatment This medicine continues to exert a therapeutic effect in skin tissue even after treatment is discontinued. Therefore, the final clinical and mycological response should preferably be assessed 2～4 weeks after the prescribed course of treatment is completed. 1) Vulvovaginal candidiasis: Administer itraconazole 200 mg per dose twice daily (morning and evening) for 1 day, or 200 mg once daily for 3 days. 2) Tinea versicolor: Administer 200 mg once daily for 7 days. 3) Tinea corporis and tinea cruris: Administer 100 mg once daily for 15 days. 4) Tinea manuum (interdigital) and tinea pedis (interdigital): Administer 100 mg once daily for 15 days. 5) Tinea manuum (palmar) and tinea pedis (plantar): Administer 100 mg once daily for 30 days or 200 mg per dose twice daily for 7 days. 6) Oral candidiasis: Administer 100 mg once daily for 15 days. 7) Fungal keratitis: Administer 200 mg once daily for 21 days. 2. Onychomycosis 1) Pulse therapy Administer 200 mg per dose twice daily for 1 week, followed by a 3-week treatment-free interval; this constitutes 1 cycle. Treat for up to 2 cycles if only the fingernails are infected and for up to 3 cycles if the toenails are infected. Site of onychomycosis Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Toenails (with or without concomitant fingernail infection) Treatment No treatment Treatment No treatment Treatment Fingernails Treatment No treatment Treatment 2) Continuous therapy Administer 200 mg once daily for 3 months. The therapeutic effect continues for 3 months for fingernails and 6 months for toenails after treatment ends. 3. Systemic fungal infections In patients with impaired immune function, such as those with neutropenia or AIDS or those who have undergone organ transplantation, the oral bioavailability of this medicine may be reduced. If necessary, increase the dose twofold. Indication Dose Average treatment duration1 Notes Aspergillosis 200mg once daily 2~5 months For invasive or disseminated disease, increase the dose to 200mg per dose twice daily. Candidiasis 100~200mg once daily 3 weeks~7 months Cryptococcal meningitis 200mg twice daily 2 months~1 year Maintenance therapy (for patients with AIDS only): 200mg once daily2 Paracoccidioidomycosis 100mg once daily 6 months There are no efficacy data for this dosage regimen for the treatment of paracoccidioidomycosis in patients with ADIS. 1 Treatment duration should be adjusted according to clinical response. 2 Treatment duration should be based on immune recovery.

This medication can be life-threatening for patients with poor heart function or a history of heart failure, so it should not be used unless for the treatment of serious infections. Patients who have had allergic reactions to this drug or have diminished heart function, as well as patients taking certain medications should avoid this drug. Patients with poor liver function, decreased kidney function, and weakened immune systems should use this medication with caution and undergo regular liver function tests. This drug can interact with a wide range of other medications, so if you are taking other drugs, you must consult with your healthcare professional, especially when used concurrently with heart-related medications, analgesics, anticancer drugs, and antipsychotics. Women who are pregnant, may become pregnant, or are breastfeeding should not use this drug and should utilize effective contraception while taking this medication. During treatment, unusual symptoms such as dizziness, headaches, gastrointestinal disturbances, skin rashes, and hearing loss may occur, and if any symptoms occur, you should report them to your healthcare professional immediately. Caution should be taken as dizziness or visual disturbances may occur when driving or operating machinery. Do not exceed the prescribed dosage; if overdose occurs, contact a medical institution immediately for appropriate treatment. Keep out of reach of children, and store the medication in its original container to prevent misuse or quality degradation.

Decreased myocardial contractility, headache, nausea, abdominal pain, rhinitis, sinusitis, upper respiratory tract infection, leukopenia, hypersensitivity, taste disturbance, sensory impairment, sensory abnormality, tinnitus, constipation, diarrhea, dyspepsia, bloating, vomiting, liver dysfunction, hyperbilirubinemia, itching, rash, urticaria, pollakiuria, erectile dysfunction, menstrual disorders, edema, neutropenia, thrombocytopenia, anaphylactic-like reactions, hyperglycemia, hyperkalemia, hypokalemia, hypomagnesemia, altered mental status, peripheral neuropathy, dizziness, drowsiness, tremor, heart failure, left ventricular failure, tachycardia, hypertension, hypotension, pulmonary edema, speech disorders, cough, gastrointestinal disorders, liver failure, hepatitis, jaundice, erythematous rash, hyperhidrosis, myalgia, arthralgia, renal impairment, urinary incontinence, generalized edema, facial edema, chest pain, fever, pain, fatigue, chills, increased alanine aminotransferase, increased aspartate aminotransferase, increased serum alkaline phosphatase, increased serum lactate dehydrogenase, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased liver enzymes, abnormal urinalysis, leukocytosis, eosinophilia, anemia, vascular edema, serum sickness, angioedema, anaphylaxis, anaphylactic shock, allergic reactions, diplopia, visual impairment, hearing loss, ventricular premature contractions, atrial block, palpitations, increased gastrointestinal motility, belching, glossitis, stomatitis, abdominal lower back pain, pancreatitis, increased serum total protein, increased total bilirubin, increased LAP, decreased appetite, lethargy, dark urine, erythema multiforme, hair loss, photosensitivity, exfoliative dermatitis, leukocytoclastic vasculitis, acute generalized exanthematous pustulosis, increased BUN, positive urinary protein, positive urinary glucose, decreased libido, drowsiness, lethargy, shoulder stiffness, insomnia, chest pain, increased serum triglycerides, burning sensation, increased serum uric acid, increased serum potassium, serum sickness, angioedema, anaphylactic reaction, hypertriglyceridemia, tremor, visual impairment, transient hearing loss, permanent hearing loss, congestive heart failure, dyspnea, significant hepatic toxicity, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, increased serum creatine phosphokinase activity

This medication should be stored in a sealed container to prevent air from entering, ideally at room temperature between 1 and 30 degrees Celsius. This storage condition helps maintain the drug's effectiveness and prevent degradation.

Appearance

Opaque blue hard capsules filled with spherical granules that are white or light yellow on the top and pink on the bottom

Package unit

30 capsules/bottle, 100 capsules/bottle